DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

Information source: Novartis
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Relapsing Remitting Multiple Sclerosis

Intervention: Fingolimod (Drug); Disease Modifying therapy (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Novartis Pharmaceuticals

Official(s) and/or principal investigator(s):
Novartis Pharmaceuticals, Study Director, Affiliation: Novartis Pharmaceuticals

Summary

A 12 month study where 852 patients with relapsing remitting MS will be randomized 1: 1 to fingolimod or approved disease modifying therapy. Patients will be be treatment naive or have only been treated with one class of DMT (Interferon beta preparation or glatiramer acetate) . Patients will be able to switch to different treatment for safety, efficacy, tolerability or convenience during the study. Primary objective is to evaluate efficacy of fingolimod by assessing patients retention on treatment. Secondary objectives are to compare reasons for discontinuation, adverse events, cognitive impairment, medication satisfaction and change in brain volume measured by MRI.

Clinical Details

Official title: A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Retention on treatment

Secondary outcome:

Reasons for Discontinuation

Adverse events

Cognitive impairment

Percent change in brain volume

Treatment satisfaction

Detailed description: 852 Patients with relapsing remitting MS will be randomized 1: 1 to fingolimod or approved first line DMTs. Patients must be either treatment naive or have received treatment with only one class of treatment (interferon beta preparation or glatiramer acetate) . Patients previously treated with DMT and randomized to the DMT arm may not remain on the same treatment for the study and will have to switch to a different class (i. e., previously treated with glatiramer acetate will switch to interferon beta preparaption, previously treated with interferon beta preparation will swtich to glatiramer acetate). Entry criteria at screening include but are not limited to, age 18-65, diagnosis with RRMS, EDSS < or equal to 6, not pregnant or planning pregnancy and women of childbearing potential willing to use contraception throughout the study.

Exclusion criteria include but are not limited to - prior exposure to fingolimod, history of

malignancy within 5 years, other than RRMS types of MS, other diseases of the immune system, active macular edema, systemic bacterial, viral or fungal infections, patients without vaccine against varicella zoster, receipt of live or attentuated vaccines within a month of screening, history of various cardiac conditions, presence of certain ECG abnormalities, resting heart rate < 45 bpm, symptomatic bradycardia, recurrent syncope, severe untreated sleep apnea, severe pulmonary conditions, various hepatic conditions, certain neurologic disorders, pregnancy. Patients may switch treatment before 3 months for safety reasons only, after 3 months for safety, efficacy, tolerability or convenience. Treatment switch during the study may be to any of study approved treatments irrespective of prior treatment. Patients randomized to fingolimod will need to have 6 hours of observation for signs and symptoms of bradycardia following administration of the first dose. Extended observation or overnight observation may be necessary under certain circumstances. Primary objective is to evaluate efficacy of fingolimod by assessing patients retention on treatment. Secondary objectives are to compare reasons for discontinuation, adverse events, cognitive impairment, medication satisfaction and change in brain volume measured by MRI. Exploratory objectives include annualized relapse rate, OCT, MRI evaluations, biomarkers and patient reported outcome measures.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. written informed consent must be obtained prior to any assessment being performed. 2. Male and female patients aged 18-65 years inclusive. 3. Patients diagnosed with relapsing remitting MS, defined by the 2010 revised McDonald criteria (Pollman et al, 2011) (Appendix 1). 4. EDSS score of less than or equal to 6. 5. Patients naive to treatment or who have been treated with no more than one class of DMT previously (interferon β preparation or glatiramer acetate), and who, per investigator judgment, may benefit from a change of treatment class. 6. Patients who have been treated with DMF for less than 2 months total exposure and who have a normal lymphocyte count at screening. 7. Women of childbearing potential must have a negative urine and serum β-human chorionic gonadotropin (β-hCG) pregnancy test at screening and at baseline. 8. Before entry women must be:

- Post menopausal for at least 1 year, or

- Surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal

ligation or otherwise incapable of pregnancy, or

- Practicing a highly effective method of birth control if sexually active,

including hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double barrier method (e. g., condoms, diaphragm or cervical cap with spermicidal foam, cream or gel), or male partner sterilization consistent with local regulations regarding use of birth control methods for patients participating in clinical trials, for the duration of their participation in the study, or

- Not heterosexually active (patients who are not heterosexually active at

screening must agree to utilize a highly effective method of birth control if they become heterosexually active during their participation in the study) 4. 2 Exclusion criteria 1. Use of other investigational drugs within 30 days of screening. 2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes. 3. Prior exposure to fingolimod or any other S1P receptor modulating compounds. 4. History or presence of malignancy of any organ system (other than successfully treated basal or squamous cell carcinoma of the skin or stage 0 carcinoma of the cervix), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases. 5. Patients diagnosed with Secondary Progressive Multiple Sclerosis (SPMS) or Primary Progressive MS (PPMS). 6. Patients with a history of chronic disease of the immune system other than MS or a known immunodeficiency syndrome. 7. Patients who have been treated with: • Natalizumab, mitoxantrone, cladribine, rituximab, alemtuzumab, ofatumumab, ocrelizumab at any time before randomization • Immunoglobulins, or pulse of corticosteroids with more than 6 months cumulative exposure • Immunosuppressive/chemotherapeutic medications (e. g., methotrexate, azathioprine, cyclophosphamide, cellcept, Cytoxan, IVIG) with more than 6 months of cumulative exposure and within 6 months prior to randomization • Corticosteroids or adrenocorticotropic hormones in the past 30 days before randomization. Patients that require corticosteroids for a relapse during the screening period may be rescreened 30 days after the last dose. 8. History of treatment with both classes of approved first line DMT (interferon β preparation and glatiramer acetate) or DMF exposure of 2 months or longer. 9. Patients with uncontrolled diabetes mellitus (HbA1c > 7%). 10. Diagnosis of macular edema during the screening phase. Patients with a history of macular edema will be allowed to enter the study provided that they do not have macular edema at the screening visit. 11. Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS, Hepatitis B, Hepatitis C infection or positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests. 12. Patients without history of chickenpox or without vaccination against varicella-zoster virus at screening (patients may be vaccinated and rescreened one month or longer after vaccination). 13. Patients who have received any live or live attenuated vaccines (including for varicella-zoster or measles) within 1 month prior to baseline. 14. Patients with any medically unstable condition as assessed by the investigator. 15. Patients with a history of the following cardiovascular conditions: • Cardiac arrest. • myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure (Appendix 3). • Congestive heart failure. • Hypertension that is not controlled with prescribed medications. These patients may be rescreened if blood pressure is stabilized with treatment. • Cerebrovascular disease. • History or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a pacemaker. • Patients at higher risk of symptomatic bradycardia or heart block because of a coexisting medical condition or certain concomitant medications. • Patients randomized to the fingolimod arm with prolonged QTc interval at screening (corrected QT interval > 450 ms in males and > 470 ms in females); for patients randomized to the fingolimod treatment arm before dosing (baseline) or during the 6-hour observation period; and those patients at additional risk for QT prolongation (e. g., hypokalemia, hypomagnesemia, congenital long-QT syndrome), or on a concomitant therapy with QT prolonging drugs with a known risk of Torsades de pointes (e. g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin).

- Patients receiving class Ia or Class III antiarrhythmic drugs (Appendix 6)

- Patients receiving concurrent therapy with drugs that slow the heart rate or

atrioventricular conduction (e. g., beta blockers, digoxin, or heart-rate slowing calcium channel blockers such as diltiazem, verapamil or digoxin). The possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction should be evaluated by the physician prescribing these drugs before initiating fingolimod treatment.

- History of sick sinus syndrome or sinoatrial heart block.

- Resting heart rate of < 45 bpm or symptomatic bradycardia

- Recurrent syncope

- Severe untreated sleep apnea

16. Patients with severe pulmonary conditions (including severe respiratory disease, pulmonary fibrosis, active tuberculosis, severe or poorly controlled asthma). 17. Patients with any of the following hepatic conditions: • Chronic liver or biliary disease

- Total bilirubin greater than upper limit of normal (ULN) at screening unless in

the context of Gilbert's syndrome

- Conjugated bilirubin greater than the ULN at screening

- AST (SGOT), ALT (SGPT) greater than 3 times ULN at screening

- Alkaline phosphatase (AP) greater than 1. 5 times the ULN at screening

18. Serum creatinine greater than 2. 0 mg/dL (176. 5 µmol/L) at screening. 19. Patients with the following neurological/psychiatric disorders:

- History of substance abuse (drug or alcohol) in the past five years as

determined by the investigator

- Progressive neurological disorder other than MS which may affect study

participation as determined by the investigator

- Any serious psychiatric condition that may interfere with the patient's ability

to cooperate and comply with the study procedures as determined by the investigator 20. Women who are pregnant or nursing (lactating) or planning to become pregnant. 21. Any condition that in the opinion of the investigator, would compromise the well-being of the patient or the conduct of the study, or prevent the patient from meeting or performing study requirements. 22. Pre-planned surgery or medical procedure that would interfere with the conduct of the study. 23. Employee of the sponsor, investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.

Locations and Contacts

Novartis Investigative Site, Guaynabo 00969, Puerto Rico

Novartis Investigative Site, Cullman, Alabama 35058, United States

Novartis Investigative Site, Phoenix, Arizona 85004, United States

Novartis Investigative Site, Sun City, Arizona 85351, United States

Novartis Investigative Site, Tucson, Arizona 85741, United States

Novartis Investigative Site, Sherwood, Arkansas 72120, United States

Novartis Investigative Site, Fullerton, California 92835, United States

Novartis Investigative Site, Oceanside, California 92056, United States

Novartis Investigative Site, San Francisco, California 94117, United States

Novartis Investigative Site, Walnut Creek, California 94598, United States

Novartis Investigative Site, Basalt, Colorado 81621, United States

Novartis Investigative Site, Boulder, Colorado 80301, United States

Novartis Investigative Site, Denver, Colorado 80209, United States

Novartis Investigative Site, Denver, Colorado 80210, United States

Novartis Investigative Site, Fort Collins, Colorado 80528, United States

Novartis Investigative Site, Fairfield, Connecticut 06824, United States

Novartis Investigative Site, New London, Connecticut 06320, United States

Novartis Investigative Site, Dover, Delaware 19901, United States

Novartis Investigative Site, Atlantis, Florida 33462-6608, United States

Novartis Investigative Site, Bradenton, Florida 32405, United States

Novartis Investigative Site, Delray Beach, Florida 33445, United States

Novartis Investigative Site, Hollywood, Florida 33021, United States

Novartis Investigative Site, Jacksonville, Florida 32216, United States

Novartis Investigative Site, North Palm Beach, Florida 33408, United States

Novartis Investigative Site, Plantation, Florida 33324, United States

Novartis Investigative Site, Pompano Beach, Florida 33060, United States

Novartis Investigative Site, Port Charlotte, Florida 33952, United States

Novartis Investigative Site, Port Orange, Florida 32127, United States

Novartis Investigative Site, Sarasota, Florida 34233, United States

Novartis Investigative Site, Sarasota, Florida 34243, United States

Novartis Investigative Site, St. Petersburg, Florida 33713, United States

Novartis Investigative Site, Tallahassee, Florida 32308, United States

Novartis Investigative Site, Tampa, Florida 33609, United States

Novartis Investigative Site, West Palm Beach, Florida 33407, United States

Novartis Investigative Site, Atlanta, Georgia 30312, United States

Novartis Investigative Site, Columbus, Georgia 31904, United States

Novartis Investigative Site, Decatur, Georgia 30083, United States

Novartis Investigative Site, Suwanee, Georgia 30024, United States

Novartis Investigative Site, Flossmoor, Illinois 60422, United States

Novartis Investigative Site, Northbrook, Illinois 60062, United States

Novartis Investigative Site, Anderson, Indiana 46011, United States

Novartis Investigative Site, Indianapolis, Indiana 46227, United States

Novartis Investigative Site, Indianapolis, Indiana 46256, United States

Novartis Investigative Site, Des Moines, Iowa 50314-2611, United States

Novartis Investigative Site, Overland Park, Kansas, United States

Novartis Investigative Site, Wichita, Kansas 67214, United States

Novartis Investigative Site, Hawesville, Kentucky 42384, United States

Novartis Investigative Site, Lexington, Kentucky 40504, United States

Novartis Investigative Site, Madisonville, Kentucky 42431, United States

Novartis Investigative Site, Alexandria, Louisiana 71301, United States

Novartis Investigative Site, Baton Rouge, Louisiana 70809, United States

Novartis Investigative Site, New Orleans, Louisiana 70115, United States

Novartis Investigative Site, Annapolis, Maryland 21401, United States

Novartis Investigative Site, Fulton, Maryland 20759, United States

Novartis Investigative Site, New Bedford, Massachusetts 02740, United States

Novartis Investigative Site, North Dartmouth, Massachusetts 02747, United States

Novartis Investigative Site, Springfield, Massachusetts 01104, United States

Novartis Investigative Site, Watertown, Massachusetts 02472, United States

Novartis Investigative Site, Worchester, Massachusetts 01608, United States

Novartis Investigative Site, Kalamazoo, Michigan 49007, United States

Novartis Investigative Site, Traverse City, Michigan 49684-2340, United States

Novartis Investigative Site, Nixa, Missouri 65714-7807, United States

Novartis Investigative Site, North Kansas City, Missouri 64116, United States

Novartis Investigative Site, St. Louis, Missouri 63104, United States

Novartis Investigative Site, Las Vegas, Nevada 89123, United States

Novartis Investigative Site, Las Vegas, Nevada 89121, United States

Novartis Investigative Site, Las Vegas, Nevada 89144, United States

Novartis Investigative Site, Flemington, New Jersey 08822, United States

Novartis Investigative Site, Teaneck, New Jersey 07666, United States

Novartis Investigative Site, Toms River, New Jersey 08755, United States

Novartis Investigative Site, Albuquerque, New Mexico 87108, United States

Novartis Investigative Site, Albany, New York 12208, United States

Novartis Investigative Site, Amherst, New York 14226, United States

Novartis Investigative Site, Bronx, New York 10467-2490, United States

Novartis Investigative Site, Kingston, New York 12401, United States

Novartis Investigative Site, Latham, New York 12110, United States

Novartis Investigative Site, New York, New York 10003, United States

Novartis Investigative Site, Patchogue, New York 11772, United States

Novartis Investigative Site, Asheville, North Carolina 28806, United States

Novartis Investigative Site, Charlotte, North Carolina 28202, United States

Novartis Investigative Site, Charlotte, North Carolina 28204, United States

Novartis Investigative Site, Greensboro, North Carolina 27401, United States

Novartis Investigative Site, Greenville, North Carolina 27834, United States

Novartis Investigative Site, Raleigh, North Carolina 27607, United States

Novartis Investigative Site, Salisbury, North Carolina 28144, United States

Novartis Investigative Site, Winston-Salem, North Carolina 27103, United States

Novartis Investigative Site, Grand Forks, North Dakota 58201, United States

Novartis Investigative Site, Akron, Ohio 44320, United States

Novartis Investigative Site, Bellevue, Ohio 44811, United States

Novartis Investigative Site, Canton, Ohio 44718, United States

Novartis Investigative Site, Cincinnati, Ohio 45219, United States

Novartis Investigative Site, Columbus, Ohio 43221, United States

Novartis Investigative Site, Dayton, Ohio 45408, United States

Novartis Investigative Site, Toledo, Ohio 43623, United States

Novartis Investigative Site, Oklahoma City, Oklahoma 73104, United States

Novartis Investigative Site, Oklahoma City, Oklahoma 73112, United States

Novartis Investigative Site, Eugene, Oregon 97401, United States

Novartis Investigative Site, Greensburg, Pennsylvania 15601, United States

Novartis Investigative Site, Hershey, Pennsylvania 17033, United States

Novartis Investigative Site, Pittsburg, Pennsylvania 15212, United States

Novartis Investigative Site, Cranston, Rhode Island 02920, United States

Novartis Investigative Site, Indian Land, South Carolina 29707, United States

Novartis Investigative Site, Spartanburg, South Carolina 29302, United States

Novartis Investigative Site, Spartanburg, South Carolina 29307, United States

Novartis Investigative Site, Cordova, Tennessee 38018, United States

Novartis Investigative Site, Knoxville, Tennessee 37920, United States

Novartis Investigative Site, Nashville, Tennessee 37205, United States

Novartis Investigative Site, Colleyville, Texas 76034, United States

Novartis Investigative Site, Houston, Texas 77074, United States

Novartis Investigative Site, Lubbock, Texas 79410, United States

Novartis Investigative Site, North Richland Hills, Texas 76180, United States

Novartis Investigative Site, Plano, Texas 75075, United States

Novartis Investigative Site, Round Rock, Texas 78681, United States

Novartis Investigative Site, San Antonio, Texas 78229, United States

Novartis Investigative Site, Orem, Utah 84058, United States

Novartis Investigative Site, Alexandria, Virginia 22310, United States

Novartis Investigative Site, Norfolk, Virginia 23507, United States

Novartis Investigative Site, Vienna, Virginia 22182, United States

Novartis Investigative Site, Bothell, Washington 98011, United States

Novartis Investigative Site, Seattle, Washington 98101, United States

Novartis Investigative Site, Tacome, Washington 98405, United States

Novartis Investigative Site, Morgantown, West Virginia 26506-9260, United States

Novartis Investigative Site, Neenah, Wisconsin 54956, United States

Additional Information

Starting date: June 2012
Last updated: August 21, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017